<DOC>
	<DOCNO>NCT01918033</DOCNO>
	<brief_summary>This study evaluate efficacy safety desloratadine ( MK-4117 ) Japanese participant perennial allergic rhinitis . The primary hypothesis desloratadine superior placebo 2 week treatment regard change baseline Total Nasal Symptom Score among Japanese participant perennial allergic rhinitis .</brief_summary>
	<brief_title>A Study Efficacy Safety Desloratadine ( MK-4117 ) Japanese Participants With Perennial Allergic Rhinitis ( MK-4117-200 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Histamine H1 Antagonists , Non-Sedating</mesh_term>
	<mesh_term>Histamine</mesh_term>
	<mesh_term>Histamine H1 Antagonists</mesh_term>
	<criteria>Diagnosed perennial allergic rhinitis Outpatient . Lower respiratory tract infection nasopharyngolaryngeal infection ( acute upper respiratory tract infection , acute pharyngolaryngitis , acute tonsillitis , etc . ) Coexisting infection systemic mycosis effective antibiotic Asthma complication treatment Nasal septum ulcer , nasal surgery , nasal trauma , heal Vasomotor rhinitis eosinophilic rhinitis Nasal condition ( infectious sinusitis , hypertrophic rhinitis , acute chronic rhinitis , nasal polyp , septal deviation , etc . ) may interfere evaluation efficacy study drug History hypersensitivity antihistamine study drug Currently receive treatment another investigational drug receive investigational drug past 3 month Has start specific desensitization therapy nonspecific allassotherapy ( Histaglobin , vaccine therapy , etc . ) discontinue therapy within 90 day ( 3 month ) day obtain informed consent Severe hepatic , renal , cardiac , hematological disease , serious coexisting disease whose general condition poor History malignancy clinically important hematological disorder History severe drug allergy ( e.g. , anaphylactoid reaction ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Rhinitis</keyword>
	<keyword>Allergic Rhinitis</keyword>
	<keyword>Nose Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Cholinergic Antagonists</keyword>
	<keyword>Cholinergic Agents</keyword>
	<keyword>Neurotransmitter Agents</keyword>
	<keyword>Histamine H1 Antagonists , Non-Sedating</keyword>
	<keyword>Histamine H1 Antagonists</keyword>
	<keyword>Histamine Antagonists</keyword>
	<keyword>Histamine Agents</keyword>
</DOC>